Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine for Depression in Type 2 Diabetes
NCT03202095Phase 4Withdrawn
- Sponsor
- University of Utah
- Start
- Aug 2017
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in major depressive disorder (MDD), sponsored by University of Utah. Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Planned start Aug 2017; status: withdrawn.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03202095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202095.